description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.1 (S0867F0085.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


status: Public on Nov 06 2014

type: RNA

city: Pittsburgh

first: Victoria

last: Plamadeala

state: Pennsylvania

address: 2516 Jane St

country: USA

institute: Precision Therapeutics

description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.2 (S0867F0085.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

hyb_protocol: Fragmented and labelled cDNA was hybridized to HG-U133 Plus 2.0 microarray (Affymetrix) at 45C for 18 hours at a rotation speed of 60rpm. Arrays were washed and stained using the Affymetrix GeneChip Hybridization, Wash & Stain kit in the Affymetrix FS450Dx2 Fluidics Station.

scan_protocol: Arrays were scanned on the GeneChip System 3000Dx v.2 (Affymetrix) using the HG-U133+2.0 protocol.

data_processing: RefRMA

label: biotin

molecule: total RNA

organism: Homo sapiens

source_name: Lung

label_protocol: Extracted total RNA was amplified using the Ovation Pico WTA System V2 (NuGEN Technologies, Inc.) and then fragmented and labelled with the Encore Biotin Module (NuGEN Technologies, Inc.).

growth_protocol: Immediately upon surgical extraction, specimens were either flash frozen and stored at -80C or placed in RNAL. Specimens were not subjected to any type of growth environment between surgical extraction and total RNA extraction.

extract_protocol: Total RNA was extracted from each specimen via a phenol-chloroform protocol.

treatment_protocol: Specimens were treated in 2 different ways to ensure stabilization of genomic material, notably total RNA.  Specimens were either flash frozen and then stored at -80C or placed immediately in RNAL.

tag: study

value: EQUIVALENCE STUDY

tag: tissue

value: non-small-cell lung carcinoma

tag: specimen

tag: specimen treatment

value: RNALater


description:
EQUIVALENCE STUDY::Specimen-110-1;RNALater    ;'Rep.2 (S0867F0084.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;RNALater    ;'Rep.2 (S0867F0086.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;RNALater    ;'Rep.1 (S0867F0083.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;RNALater    ;'Rep.2 (S0867F0083.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2729T;Fresh Frozen;'Rep.1 (S0867F0073.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: Fresh Frozen


description:
EQUIVALENCE STUDY::Specimen-110-1;RNALater    ;'Rep.1 (S0867F0084.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-4424T;Fresh Frozen;'Rep.1 (S0867F0081.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-4374T;Fresh Frozen;'Rep.2 (S0867F0077.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-1;RNALater    ;'Rep.1 (S0867F0087.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2834T;Fresh Frozen;'Rep.1 (S0867F0074.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2898T;Fresh Frozen;'Rep.1 (S0867F0075.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-4424T;Fresh Frozen;'Rep.2 (S0867F0081.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-4374T;Fresh Frozen;'Rep.1 (S0867F0077.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2123T;Fresh Frozen;'Rep.2 (S0867F0066.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2311T;Fresh Frozen;'Rep.1 (S0867F0069.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2531T;Fresh Frozen;'Rep.2 (S0867F0071.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2482T;Fresh Frozen;'Rep.2 (S0867F0070.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2898T;Fresh Frozen;'Rep.2 (S0867F0075.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2482T;Fresh Frozen;'Rep.1 (S0867F0070.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2311T;Fresh Frozen;'Rep.2 (S0867F0069.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2531T;Fresh Frozen;'Rep.1 (S0867F0071.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2212T;Fresh Frozen;'Rep.1 (S0867F0068.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2212T;Fresh Frozen;'Rep.2 (S0867F0068.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2123T;Fresh Frozen;'Rep.1 (S0867F0066.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1912T;Fresh Frozen;'Rep.1 (S0867F0064.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2046T;Fresh Frozen;'Rep.1 (S0867F0065.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2046T;Fresh Frozen;'Rep.2 (S0867F0065.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1750T;Fresh Frozen;'Rep.2 (S0867F0061.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1869T;Fresh Frozen;'Rep.2 (S0867F0063.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1869T;Fresh Frozen;'Rep.1 (S0867F0063.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1667T;Fresh Frozen;'Rep.2 (S0867F0058.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1912T;Fresh Frozen;'Rep.2 (S0867F0064.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1701T;Fresh Frozen;'Rep.1 (S0867F0060.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1701T;Fresh Frozen;'Rep.2 (S0867F0060.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-110-0;RNALater    ;'Rep.1 (S0867F0097.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1518T;Fresh Frozen;'Rep.1 (S0867F0056.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1492T;Fresh Frozen;'Rep.1 (S0867F0055.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1750T;Fresh Frozen;'Rep.1 (S0867F0061.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1667T;Fresh Frozen;'Rep.1 (S0867F0058.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1518T;Fresh Frozen;'Rep.2 (S0867F0056.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1256T;Fresh Frozen;'Rep.2 (S0867F0054.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2834T;Fresh Frozen;'Rep.2 (S0867F0074.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0672T;Fresh Frozen;'Rep.2 (S0867F0050.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1492T;Fresh Frozen;'Rep.2 (S0867F0055.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1256T;Fresh Frozen;'Rep.1 (S0867F0054.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0672T;Fresh Frozen;'Rep.1 (S0867F0050.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0864T;Fresh Frozen;'Rep.2 (S0867F0053.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0620T;Fresh Frozen;'Rep.1 (S0867F0049.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0864T;Fresh Frozen;'Rep.1 (S0867F0053.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0620T;Fresh Frozen;'Rep.2 (S0867F0049.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0859T;Fresh Frozen;'Rep.1 (S0867F0052.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0595T;Fresh Frozen;'Rep.2 (S0867F0048.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0350T;Fresh Frozen;'Rep.2 (S0867F0046.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0350T;Fresh Frozen;'Rep.1 (S0867F0046.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0298T;Fresh Frozen;'Rep.2 (S0867F0043.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0222T;Fresh Frozen;'Rep.2 (S0867F0042.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0338T;Fresh Frozen;'Rep.2 (S0867F0045.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0595T;Fresh Frozen;'Rep.1 (S0867F0048.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0338T;Fresh Frozen;'Rep.1 (S0867F0045.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2898T;RNALater    ;'Rep.2 (S0867F0034.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-4374T;RNALater    ;'Rep.1 (S0867F0036.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2834T;RNALater    ;'Rep.1 (S0867F0033.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2834T;RNALater    ;'Rep.2 (S0867F0033.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2531T;RNALater    ;'Rep.1 (S0867F0030.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0298T;Fresh Frozen;'Rep.1 (S0867F0043.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2482T;RNALater    ;'Rep.2 (S0867F0029.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2729T;RNALater    ;'Rep.2 (S0867F0032.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2482T;RNALater    ;'Rep.1 (S0867F0029.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2212T;RNALater    ;'Rep.1 (S0867F0027.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2123T;RNALater    ;'Rep.1 (S0867F0025.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2898T;RNALater    ;'Rep.1 (S0867F0034.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2531T;RNALater    ;'Rep.2 (S0867F0030.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2311T;RNALater    ;'Rep.1 (S0867F0028.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0222T;Fresh Frozen;'Rep.1 (S0867F0042.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2729T;RNALater    ;'Rep.1 (S0867F0032.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-4424T;RNALater    ;'Rep.2 (S0867F0040.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-4374T;RNALater    ;'Rep.2 (S0867F0036.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-4424T;RNALater    ;'Rep.1 (S0867F0040.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2046T;RNALater    ;'Rep.2 (S0867F0024.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2212T;RNALater    ;'Rep.2 (S0867F0027.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0859T;Fresh Frozen;'Rep.2 (S0867F0052.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2311T;RNALater    ;'Rep.2 (S0867F0028.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2123T;RNALater    ;'Rep.2 (S0867F0025.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2046T;RNALater    ;'Rep.1 (S0867F0024.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1912T;RNALater    ;'Rep.2 (S0867F0023.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1912T;RNALater    ;'Rep.1 (S0867F0023.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1869T;RNALater    ;'Rep.2 (S0867F0022.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1701T;RNALater    ;'Rep.1 (S0867F0019.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1667T;RNALater    ;'Rep.2 (S0867F0017.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1750T;RNALater    ;'Rep.2 (S0867F0020.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1518T;RNALater    ;'Rep.1 (S0867F0015.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1667T;RNALater    ;'Rep.1 (S0867F0017.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1869T;RNALater    ;'Rep.1 (S0867F0022.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1701T;RNALater    ;'Rep.2 (S0867F0019.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0864T;RNALater    ;'Rep.2 (S0867F0012.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1750T;RNALater    ;'Rep.1 (S0867F0020.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0620T;RNALater    ;'Rep.1 (S0867F0008.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1256T;RNALater    ;'Rep.2 (S0867F0013.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1518T;RNALater    ;'Rep.2 (S0867F0015.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0859T;RNALater    ;'Rep.1 (S0867F0011.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0338T;RNALater    ;'Rep.2 (S0867F0004.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1256T;RNALater    ;'Rep.1 (S0867F0013.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0338T;RNALater    ;'Rep.1 (S0867F0004.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0859T;RNALater    ;'Rep.2 (S0867F0011.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1492T;RNALater    ;'Rep.1 (S0867F0014.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0864T;RNALater    ;'Rep.1 (S0867F0012.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0350T;RNALater    ;'Rep.2 (S0867F0005.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0595T;RNALater    ;'Rep.1 (S0867F0007.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0350T;RNALater    ;'Rep.1 (S0867F0005.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0672T;RNALater    ;'Rep.1 (S0867F0009.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0672T;RNALater    ;'Rep.2 (S0867F0009.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0595T;RNALater    ;'Rep.2 (S0867F0007.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0620T;RNALater    ;'Rep.2 (S0867F0008.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0298T;RNALater    ;'Rep.2 (S0867F0002.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-2729T;Fresh Frozen;'Rep.2 (S0867F0073.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-1492T;RNALater    ;'Rep.2 (S0867F0014.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0222T;RNALater    ;'Rep.2 (S0867F0001.2)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
EQUIVALENCE STUDY::Specimen-0298T;RNALater    ;'Rep.1 (S0867F0002.1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.


description:
ACCURACY STUDY::Specimen-S0867F0100.2.Lab 1 (S0867F0100.2.Lab 1)
Tissues included in these studies were required to be histologically confirmed as adenocarcinoma, squamous or large cell carcinoma; to not have been previously treated with chemotherapy, targeted therapy or radiation therapy; to contain a minimum of 20% tumor; to be collected and treated with RNAL medium within one hour of surgical resection; to remain in the solution for at least 24 hours at 4°C for adequate stabilization; and upon receipt, to be removed from the reagent and frozen at -80°C until RNA extraction.   Also, to ensure sufficient penetration of RNAlater into tissues, it was required that the minimal ratio of RNAlater to tissue volume be 10:1 and at least one dimension of the tissue be no more than 5mm.

value: ACCURACY STUDY

tag: lab